Hot keywords:Tobramycin sulfate injection / bupivacaine hydrochloride injection / amlodipine besylate tablets / bupivacaine hydrochloride injection |
Search
|
Anhui Changjiang Pharmaceutical Co., Ltd. is located in Wuhu, Anhui Province, which is a beautiful and rich "giant port of the Yangtze River and the backbone of Anhui Province". Wuhu is located in the northwest of the Yangtze River Delta, with superior geographical position, adjacent to the river and offshore, connecting the East with the west, connecting the South with the north, with convenient transportation and beautiful environment. Wuhu is also an important comprehensive transportation hub in China. Wuhu port, with the fifth largest port in the Yangtze River, is the larger foreign trade terminal in Anhui Province.
Tel: 0553-2245066 (domestic sales) 0553-2245055 (export sales)
Business Scope: Licensed Items: Pharmaceutical Production: Drug Entrusted Production: Class II Medical Device Production (Items subject to approval in accordance with the law can only carry out business activities after being approved by the relevant departments. The specific business projects are subject to the approval documents or licenses of the relevant departments. )
Registered capital: 70 million yuan ...... |
Anhui Changjiang pharmaceutical factory (state-owned enterprise, established in 1954)
The current director, Mr. Guilin, restructured and reorganized the company
Three dosage forms of the company passed national GMP certification at one time
The enterprise technology research center has been set up, and the foreign trade has obtained the independent export right
Anhui Province "pharmaceutical production management, efficiency" double excellent "enterprises and national" high tech enterprises "
The new version of GMP I was approved in March
In March, Shuizhen II workshop passed the national new GMP certification
In August, the solid workshop passed the national new GMP certification
In July, the company was renamed Anhui Changjiang Pharmaceutical Co., Ltd
MARKETING STRATEGY 1. Protection of existing products and key products; BUSINESS SITUATION Domestic market accounts for 60% At present, 24 provinces and cities in China have established sales networks and participated in bidding, and the products have been sold by pharmaceutical companies. Among them, East China and central China are the main markets Export 30% It has been registered in more than 20 overseas countries and regions, mainly to Eastern Europe, South America, Africa, the Middle East and Southeast Asia Cooperative production 10% It has successively cooperated with well-known domestic pharmaceutical enterprises, including Shanghai Pharmaceutical Group, China Resources medicine, JIUZHOUTONG Pharmaceutical Group, etc |